The DOI matches its Crossref record.
Duloxetine in the Treatment of Major Depressive Disorder: A Double-Blind Clinical Trial
Abstract
BACKGROUND: Duloxetine hydrochloride, a dual reuptake inhibitor of serotonin and norepinephrine, was evaluated for therapeutic efficacy and safety/tolerability in the treatment of major depression. METHOD: In an 8-week multicenter, double-blind, placebo-controlled study, 173 patients (aged 18-65 years) with DSM-IV major depressive disorder were randomly allocated to receive placebo (N = 70), duloxetine (N = 70), or fluoxetine, 20 mg q.d. (N = 33). Duloxetine dose was titrated in the first 3 weeks in a forced-titration regimen from 40 mg (20 mg b.i.d.) to 120 mg/day (60 mg b.i.d.). Patients were required to have a Clinical Global Impressions (CGI)-Severity of Illness scale score of at least moderate severity (> or = 4) and a 17-item Hamilton Rating Scale for Depression (HAM-D-17) total score of at least 15. Patients could not have had any current primary DSM-IV Axis I diagnosis other than major depressive disorder, or any anxiety disorder as a primary diagnosis within the past year, excluding specific phobias. The primary efficacy measurement was the HAM-D-17 total score, and secondary measures included the Montgomery-Asberg Depression Rating Scale, CGI-Severity of Illness and CGI-Improvement, and Patient Global Impression of Improvement. Safety was evaluated by recording the occurrence of discontinuation rates and treatment-emergent adverse events and by measurement of vital signs and laboratory analytes. RESULTS: Duloxetine was superior to placebo in change on the HAM-D-17 (p = .009). Estimated probabilities of response and remission were 64% and 56%, respectively, for duloxetine, compared with 52% and 30% for fluoxetine and 48% and 32% for placebo. Duloxetine was numerically superior to fluoxetine on the primary and most of the secondary outcome measures. In general, duloxetine was well tolerated; 76% of patients achieved the maximum dose, and insomnia and asthenia were the only adverse events reported statistically significantly (p < .05) more frequently by duloxetine-treated patients compared with placebo-treated patients. CONCLUSION: These data indicate that duloxetine is efficacious for the treatment of major depressive disorder and is well tolerated and safe.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Duloxetine is a well-tolerated, efficacious [28–30] SNRI antidepressant”
Citations
Cited by
Sorted by citations
Items 101–200 of 335
Bosker, F. J., Westerink, B. H. C., Cremers, T. I. F. H., Gerrits, M., van der Hart, M. G. C., Kuipers, S. D., van der Pompe, G., Horst, G. J. T., den Boer, J. A., & Korf, J. (2004) · CNS Drugs · doi:10.2165/00023210-200418110-00002 · Cited by 55
A structured approach to choosing estimands and estimators in longitudinal clinical trials
Mallinckrodt, C. H., Lin, Q., Lipkovich, I. A., & Molenberghs, G. (2012) · Pharmaceutical Statistics · doi:10.1002/pst.1536 · Cited by 50
Self-citationSafety and adverse event profile of duloxetine
Wernicke, J., Gahimer, J., Yalcin, I., Wulster-Radcliffe, M. C., & Viktrup, L. (2005) · Expert Opinion on Drug Safety · doi:10.1517/14740338.4.6.987 · Cited by 55
“Since 1997, numerous articles have been published that include descriptions of adverse events reported in Phase II and Phase III clinical trials and clinical trial continuations for MDD [2-5], DPNP [2] and SUI [6-9].”
BackgroundMachado, M., & Einarson, T. R. (2009) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2009.01050.x · Cited by 52
“ITT Alves (1999) (45) 0Æ500 0Æ079 40 0Æ404 0Æ072 47 1Æ47 0Æ63 3Æ45 Ballus (2000) (29) 0Æ561 0Æ078 41 0Æ326 0Æ071 43 2Æ65 1Æ09 6Æ43 Bielsky (2004) (46) 0Æ420 0Æ049 100 0Æ505 0Æ051 97 0Æ71 0Æ40 1Æ24 Costa e Silva (1998) (47) 0Æ602 0Æ035 196 0Æ602 0Æ036 186 1Æ00 0Æ66 1Æ51 Detke (2004) (48) 0Æ505 0Æ052 93 0Æ471 0Æ054 85 1…”
Vis, P., van Baardewijk, M., & Einarson, T. R. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1g076 · Cited by 51
Lee, P., Shu, L., Xu, X., Wang, C., Lee, M. S., LIU, C., Hong, J. P., Ruschel, S. I., Raskin, J., Colman, S. A., et al. (2007) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2007.01666.x · Cited by 50
Gupta, S., Nihalani, N. D., & Masand, P. S. (2007) · Annals of Clinical Psychiatry · doi:10.1080/10401230701333319 · Cited by 51
A Case Study of Salami Slicing: Pooled Analyses of Duloxetine for Depression
Spielmans, G. I., Biehn, T. L., & Sawrey, D. L. (2009) · Psychotherapy and Psychosomatics · doi:10.1159/000270917 · Cited by 50
Chemoenzymatic synthesis of (S)-duloxetine using carbonyl reductase from Rhodosporidium toruloides
Chen, X., Liu, Z., Lin, C.-P., & Zheng, Y. (2016) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2016.02.002 · Cited by 48
Effects of the Antidepressant Duloxetine on Body Weight
Wise, T. N., David, P., Pangallo, B. A., Losin, W. G., & Wiltse, C. G. (2006) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v08n0503 · Cited by 48
Youdim, M. B. H. (2010) · Experimental Neurobiology · doi:10.5607/en.2010.19.1.1 · Cited by 47
“One example, duloxetine (Cymbalta R ), used in the treatment of depression, inhibits both serotonin and norepinepherine uptake in the central nervous system (CNS) (Wong et al., 1988; KiharaIkeda, 1995; Goldstein et al., 2002).”
MethodTreatment of Depression in Patients with Coronary Heart Disease
Vieweg, W. V. R., Julius, D. A., Fernandez, A., Wulsin, L. R., Mohanty, P. K., Beatty-Brooks, M., Hasnain, M., & Pandurangi, A. K. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.02.037 · Cited by 50
Effects of Varying Degrees of Renal Impairment on the Pharmacokinetics of Duloxetine
Lobo, E. D., Heathman, M. A., Kuan, H., et al. (2010) · Clinical Pharmacokinetics · doi:10.2165/11319330-000000000-00000 · Cited by 45
The Safety and Tolerability of Duloxetine Compared With Paroxetine and Placebo
Nelson, J. C., Pritchett, Y., Martynov, O., Yu, J., Mallinckrodt, C. H., & Detke, M. J. (2006) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v08n0404 · Cited by 44
Self-citationArmstrong, D. G., Chappell, A. S., Le, T. K., Kajdasz, D. K., Bačkonja, M., D’Souza, D. N., & Russell, J. M. (2007) · Pain Medicine · doi:10.1111/j.1526-4637.2007.00276.x · Cited by 43
Demitrack, M. A., & Thase, M. E. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4312 · Cited by 43
Self-citationHurley, D. J., Turner, C. L., Yalcin, I., et al. (2005) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2005.08.006 · Cited by 42
Youdim, M. B. H., Geldenhuys, W. J., & der Schyf, C. J. V. (2007) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(08)70017-8 · Cited by 42
“This drug is used in the treatment of depression, and inhibits both serotonin and norepinephrine uptake in the central nervous system (CNS) [29–31].”
Kirwin, J. L., & Gören, J. L. (2005) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.25.3.396.61600 · Cited by 42
Wohlreich, M. M., Mallinckrodt, C. H., Watkin, J. G., & Hay, D. P. (2004) · BMC Geriatrics · doi:10.1186/1471-2318-4-11 · Cited by 40
“The efficacy of duloxetine in the acute treatment of MDD has been established in randomized, double-blind, placebo-controlled studies in patients aged 18 and older [8-11].”
BackgroundSelf-citationLess Is More in Antidepressant Clinical Trials
Rutherford, B. R., Cooper, T. M., Persaud, A. D., Brown, P. J., Sneed, J. R., & Roose, S. P. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12r08267 · Cited by 41
Adverse reactions to duloxetine in depression
Bitter, I., Filipovits, D., & Czobor, P. (2011) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2011.582037 · Cited by 38
“Randomized controlled studies comparing the efficacy and safety of duloxetine to SSRIs -- paroxetine and fluoxetine -- in the treatment of MDD found no significant difference in the frequency of treatment emergent adverse events (TEAEs) [45-50].”
BackgroundMishra, G. D., Barker, M. S., Herber-Gast, G.-C., et al. (2015) · Maturitas · doi:10.1016/j.maturitas.2015.05.006 · Cited by 39
Fochtmann, L. J., & Gelenberg, A. J. (2005) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.3.1.34 · Cited by 38
“Randomized, clinical trials show duloxetine to be more efficacious than placebo (25–28) and comparable in efficacy to SSRI antidepressants (27, 28).”
BackgroundDefining Efficacy Estimands in Clinical Trials: Examples Illustrating ICH E9(R1) Guidelines
Ratitch, B., Goel, N., Mallinckrodt, C. H., Bell, J., Bartlett, J. W., Molenberghs, G., Singh, P., Lipkovich, I. A., & O’Kelly, M. (2020) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-019-00065-7 · Cited by 37
Self-citationFluoxetine versus other types of pharmacotherapy for depression (Review)
Cipriani, A., Brambilla, P., Furukawa, T. A., Geddes, J. R., Gregis, M., Hotopf, M. H., Malvini, L., & Barbui, C. (2005) · Cited by 39
Evidence for the efficacy of duloxetine in treating mild, moderate, and severe depression
Shelton, R. C., Andorn, A. C., Mallinckrodt, C. H., Wohlreich, M. M., Raskin, J., Watkin, J. G., & Detke, M. J. (2007) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32821c6189 · Cited by 39
“Safety and efficacy results from Studies 1 (Goldstein et al., 2002), 4 (Goldstein et al., 2004), 5 (Detke et al., 2002a), 6 (Detke et al., 2002b), 7 (Detke et al., 2004), 8 (Perahia et al., 2006), and 9 (Raskin et al., in press) have been published or presented previously.”
BackgroundDuloxetine plasma level and antidepressant response
Donatis, D. D., Florio, V., Porcelli, S., Saria, A., Mercolini, L., Serretti, A., & Conca, A. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.01.001 · Cited by 38
“Although its efficacy and tolerability in the treatment of MDD has been demonstrated at various dosages (ranging from 40 to 120mg daily) (Detke et al., 2002; Goldstein et al., 2002; Perahia et al., 2006), more recent studies suggested that a fixed dose of”
Monoamine reuptake inhibitors: highlights of recent research developments
Walter, M. W. (2005) · Drug Development Research · doi:10.1002/ddr.20013 · Cited by 38
“In clinical studies, duloxetine was observed to be more effective than fluoxetine and paroxetine on several measures of depression [Bymaster et al., 2005; Goldstein et al., 2002].”
BackgroundDuloxetine: mechanism of action at the lower urinary tract and Onuf?s nucleus
Jost, W. H., & Marsalek, P. (2004) · Clinical Autonomic Research · doi:10.1007/s10286-004-0197-8 · Cited by 38
Duloxetine Is Effective in Treating Depression in Multiple Sclerosis Patients
Solaro, C. M., Bergamaschi, R., Rezzani, C., Mueller, M., Trabucco, E., Bargiggia, V., Dematteis, F., Mattioda, A., Cimino, V., Restivo, D. A., et al. (2013) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3182996400 · Cited by 39
Urinary Side Effects of Duloxetine in the Treatment of Depression and Stress Urinary Incontinence
Viktrup, L., Pangallo, B. A., Detke, M. J., & Zinner, N. R. (2004) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v06n0204 · Cited by 37
Keeley, R. D., Smith, J. L., Nutting, P. A., Dickinson, L. M., Dickinson, W. P., & ROST, K. M. (2004) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2004.30611.x · Cited by 36
The Effects of Supratherapeutic Doses of Duloxetine on Blood Pressure and Pulse Rate
Derby, M. A., Zhang, L., Chappell, J. C., Gonzales, C., Callaghan, J. T., Leibowitz, M. T., Ereshefsky, L., Hoelscher, D. D., Leese, P. T., & Mitchell, M. I. (2007) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e31804d1cce · Cited by 36
Choi, H.-S., Park, J. H., Ahn, J. H., Hong, S., Cho, J. H., Won, M., & Lee, C. H. (2015) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2015.10.001 · Cited by 35
Taylor, A. P., Adelman, J. U., & Freeman, M. C. (2007) · Headache The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2007.00886.x · Cited by 35
The General and Comparative Efficacy and Safety of Duloxetine in Major Depressive Disorder
Gartlehner, G., Thaler, K. J., Hansen, R. A., & Gaynes, B. N. (2009) · Drug Safety · doi:10.2165/11318930-000000000-00000 · Cited by 34
Russell, J. M., Weisberg, R. B., D, M. F. M., Hartford, J. T., Erickson, J., & D’Souza, D. N. (2007) · Depression and Anxiety · doi:10.1002/da.20337 · Cited by 36
“In clinical studies, duloxetine also has been shown to be safe and effective in the treatment of depression [Detke et al., 2002a,b; Goldstein et al., 2002, 2004a; Hudson et al., 2005; Mallinckrodt et al., 2003; Nemeroff et al., 2002], diabetic peripheral neuropathic pain [Goldstein et al., 2005;…”
BackgroundDuloxetine in the treatment of major depressive disorder: an open-label study
Hudson, J. I., David, P., Gilaberte, I., Wang, F., Watkin, J. G., & Detke, M. J. (2007) · BMC Psychiatry · doi:10.1186/1471-244x-7-43 · Cited by 34
“Secondly, the study was of 12 weeks duration and therefore the results are applicable only to acute phase treatment of MDD. Thirdly, patients received a fixed 60 mg dose of duloxetine throughout the study, although the option of a temporary downward titration to 30 mg QD was available at the beginning of the treatment…”
InfluentialDuloxetine: A Dual Reuptake Inhibitor
Dugan, S. E., & Fuller, M. A. (2004) · Annals of Pharmacotherapy · doi:10.1345/aph.1e084 · Cited by 35
Wohlreich, M. M., Mallinckrodt, C. H., Prakash, A., Watkin, J. G., & Carter, W. P. (2006) · Depression and Anxiety · doi:10.1002/da.20209 · Cited by 37
“Whereas some of these studies incorporated an initial dose escalation phase (from 40 mg/day to 80 mg/day [Detke et al., 2004] or 120 mg/day [Detke et al., 2004; Goldstein et al., 2002]), the doses were administered under a twice-daily dosing regimen.”
Self-citationLee, T.-K., Park, J. H., Ahn, J. H., Shin, M. C., Cho, J. H., Bae, E. J., Kim, Y., Won, M., & Lee, C. H. (2016) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2016.09.059 · Cited by 34
Bonuccelli, U., Meco, G., Fabbrini, G., Tessitore, A., Pierantozzi, M., Stocchi, F., Ceravolo, R., Caltagirone, C., Silvestrini, M., Morgante, F., et al. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.736490 · Cited by 35
“Furthermore, the decision to start with 30 mg/day of duloxetine for the first week of treatment is justified by previous studies suggesting that initial dosing of 30 mg once daily is better tolerated than the double dose [32-35].”
BackgroundDünner, D. L., D’Souza, D. N., Kajdasz, D. K., Detke, M. J., & Russell, J. M. (2005) · Journal of Affective Disorders · doi:10.1016/j.jad.2005.02.017 · Cited by 34
Emerging therapies for neuropathic pain
Collins, S. D., & Chessell, I. P. (2005) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.10.1.95 · Cited by 34
Duloxetine for the Treatment of Major Depressive Disorder in Women Ages 40 to 55 Years
Burt, V. K., Wohlreich, M. M., Mallinckrodt, C. H., Detke, M. J., Watkin, J. G., & Stewart, D. E. (2005) · Psychosomatics · doi:10.1176/appi.psy.46.4.345 · Cited by 33
Self-citationDuloxetine in the treatment of major depressive disorder
GOLDSTEIN, D. J. (2007) · Neuropsychiatric Disease and Treatment · doi:10.2147/nedt.2007.3.2.193 · Cited by 33
Self-citationNelson, J. C., Zhang, Q., Deberdt, W. G., Marangell, L. B., Karamustafalıoğlu, O., & Lipkovich, I. A. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.654010 · Cited by 32
Satonin, D. K., McCulloch, J. D., Kuo, F., & Knadler, M. P. (2007) · Journal of Chromatography B · doi:10.1016/j.jchromb.2007.02.025 · Cited by 31
Effects of antidepressants on QT interval in people with mental disorders
Aronow, W. S., & Shamliyan, T. (2020) · Archives of Medical Science · doi:10.5114/aoms.2019.86928 · Cited by 36
Kleckner, I. R., Jusko, T. A., Culakova, E., Chung, K., Kleckner, A. S., Asare, M., Inglis, J. E., Loh, K. P., Peppone, L. J., Miller, J. M., et al. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06304-6 · Cited by 31
Wohlreich, M. M., Sullivan, M. D., Mallinckrodt, C. H., Chappell, A. S., Oakes, T. M. M., Watkin, J. G., & Raskin, J. (2009) · Psychosomatics · doi:10.1176/appi.psy.50.4.402 · Cited by 30
Self-citationDünner, D. L., Wohlreich, M. M., Mallinckrodt, C. H., Watkin, J. G., & D, M. F. M. (2005) · Current Therapeutic Research · doi:10.1016/j.curtheres.2005.12.003 · Cited by 31
Self-citationPain Relief in Depressive Disorders
Gebhardt, S., Heinzel‐Gutenbrunner, M., & König, U. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000604 · Cited by 30
Duloxetine in the treatment of major depressive disorder: comparisons of safety and efficacy.
Bailey, R. K., Mallinckrodt, C. H., Wohlreich, M. M., Watkin, J. G., & Plewes, J. M. (2006) · PubMed Central · Cited by 30
Self-citationItem-based analysis of the effects of duloxetine in depression: a patient-level post hoc study
Lisinski, A., Hieronymus, F., Näslund, J., Nilsson, S., & Eriksson, E. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0523-4 · Cited by 29
Stewart, D. E., Wohlreich, M. M., Mallinckrodt, C. H., Watkin, J. G., & Kornstein, S. G. (2006) · Journal of Affective Disorders · doi:10.1016/j.jad.2006.04.006 · Cited by 29
Self-citationDhillon, S. (2012) · Drugs & Aging · doi:10.1007/s40266-012-0040-1 · Cited by 28
Nakagawa, A., Watanabe, N., Omori, I. M., Barbui, C., Cipriani, A., McGuire, H., Churchill, R. C., & Furukawa, T. A. (2008) · CNS Drugs · doi:10.2165/00023210-200822070-00004 · Cited by 28
Mancini, M., Wade, A. G., Perugi, G., Lenox‐Smith, A., & Schacht, A. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.01.001 · Cited by 28
Single-action versus dual-action antidepressants.
Jain, R. (2004) · PubMed Central · Cited by 28
Eckert, L., & Lançon, C. (2006) · BMC Psychiatry · doi:10.1186/1471-244x-6-30 · Cited by 27
“[12] DSM-IV, Age ≥ 18 HAM-D17 ≥ 15, CGI-S ≥ 4 41 0.”
Update on duloxetine for the management of stress urinary incontinence
Duckett, J., & Basu, M. (2008) · Clinical Interventions in Aging · doi:10.2147/cia.s4062 · Cited by 27
AHL, J. S. B., Perahia, Bangs, M. E., Zhang, Cheng, Y., Frakes, E. P., Adams, M. L., & Martinez, J. M. (2013) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s45445 · Cited by 26
Torta, R., Leombruni, P., Borio, R., & Castelli, L. (2011) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1202 · Cited by 26
SNRIs Versus SSRIs: Mechanisms of Action in Treating Depression and Painful Physical Symptoms
Sussman, N. (2003) · The Primary Care Companion to The Journal of Clinical Psychiatry · Cited by 26
Duloxetine: a new selective and dual-acting antidepressant
Bauer, M., Möller, H., & Schneider, E. M. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.4.421 · Cited by 27
“1 Antidepressive activity Duloxetine’s efficacy and safety have been demonstrated in a number of placebo-controlled, double-blind trials [19-24] and in long-term studies [25,26].”
BackgroundDuloxetine 60 mg once daily in the treatment of milder major depressive disorder
David, P., Kajdasz, D. K., Walker, D. J., Raskin, J., & Tylee, A. T. (2006) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2006.00956.x · Cited by 26
Effect of duloxetine on tolterodine pharmacokinetics in healthy volunteers
Hua, T. C., Pan, A. X., Chan, C., et al. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2004.02068.x · Cited by 26
Qualitative review of SNRIs in anxiety.
Silverstone, P. H. (2004) · PubMed · Cited by 26
Fava, M., Martinez, J. M., Greist, J., Marangell, L. B., Brown, E., Chen, L., & Wohlreich, M. M. (2007) · Annals of Clinical Psychiatry · doi:10.1080/10401230701465178 · Cited by 25
Mancini, M., Perna, G., Rossi, A., & Petralia, A. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656561003747441 · Cited by 25
“1 Major depressive disorder with comorbid anxiety For the purpose of reviewing duloxetine’s efficacy in treating anxiety associated with MDD, a theoretical review [40] based on four studies was published in 2003 [15,41-43].”
BackgroundIntensive monitoring of duloxetine: results of a web-based intensive monitoring study
Härmark, L., van Puijenbroek, E., & van Grootheest, K. (2012) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-012-1313-7 · Cited by 25
“The efficacy and safety of duloxetine for the treatment of the registered indications were investigated in clinical trials [1, 3–6].”
BackgroundResultAnti-nociceptive effect of duloxetine in mouse model of diabetic neuropathic pain.
Kuhad, A., Bishnoi, M., & Chopra, K. (2009) · PubMed · Cited by 25
Antidepressant Use in Chronic Pain Management
Leo, R. J., & Barkin, R. L. (2003) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v05n0303 · Cited by 23
“, paroxetine and fluoxetine.(1,2) In premarketing trials of duloxetine, there has been a concerted effort to frame a unique niche for duloxetine’s efficacy, i.”
BackgroundÖzcan, L., Polat, E. C., Ötünçtemur, A., & Özbek, E. (2015) · International Urology and Nephrology · doi:10.1007/s11255-014-0905-9 · Cited by 24
Meta-analysis: Second generation antidepressants and headache
Telang, S., Walton, C., Olten, B., & Bloch, M. H. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.04.047 · Cited by 23
An Open-label Study of Duloxetine for the Treatment of Major Depressive Disorder
Wohlreich, M. M., Martinez, J. M., Mallinckrodt, C. H., Prakash, A., Watkin, J. G., & D, M. F. M. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000185429.10053.c8 · Cited by 23
Self-citationManagement of major depressive disorder
Tordrup, D., & Cuijpers, P. J. (2014) · VU Research Portal · Cited by 22
The role of duloxetine in the treatment of anxiety disorders
Berardis, D. D. (2008) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s2546 · Cited by 21
Dodd, S., Berk, M., Kelin, K., Mancini, M., & Schacht, A. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.04.016 · Cited by 20
Chappell, J., He, J., Knadler, M. P., et al. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009344335 · Cited by 21
Placebo Control Groups in Trials of Major Depressive Disorder Among Older Patients
Walsh, B. T., & Sysko, R. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000162810.76947.bf · Cited by 21
Immediate Switching of Antidepressant Therapy: Results from a Clinical Trial of Duloxetine
Wohlreich, M. M., Mallinckrodt, C. H., Watkin, J. G., wilson, M., Greist, J., Delgado, P. L., & D, M. F. M. (2005) · Annals of Clinical Psychiatry · doi:10.1080/10401230500296402 · Cited by 21
Self-citationDodd, S., Berk, M., Kelin, K., Zhang, Q., Eriksson, E., Deberdt, W. G., & Nelson, J. C. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.05.014 · Cited by 22
“…Wise et al., 2007; Brannan et al., 2005; Oakes et al., 2012) or any of the selective serotonin reuptake inhibitors (SSRIs), citalopram, fluoxetine (Goldstein et al., 2002; Martinez et al., 2012), paroxetine (Goldstein et al., 2004 ; Detke et al., 2004; Perahia et al., 2006; Martinez et al., 2012;…”
Minami, K., Tamano, R., Kasai, E., Ōyama, H., Hasegawa, M., Shinohara, S., & Asaki, T. (2017) · European Journal of Pain · doi:10.1002/ejp.1125 · Cited by 20
Evidence-informed management of chronic low back pain with adjunctive analgesics
Chang, V. T.-S., Gonzalez, P. G., & Akuthota, V. (2008) · The Spine Journal · doi:10.1016/j.spinee.2007.10.006 · Cited by 21
The well of novel antidepressants: running dry
Blier, P. (2010) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.100098 · Cited by 20
Effects of Duloxetine on Norepinephrine and Serotonin Transporter Activity in Healthy Subjects
Chappell, J. C., Eisenhofer, G., Owens, M. J., Haber, H. E., Lachno, D. R., Dean, R. A., Knadler, M. P., Nemeroff, C. B., Mitchell, M. I., Detke, M. J., et al. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000061 · Cited by 19
Tafseer, S., Gupta, R., Ahmad, R. S., Jain, S., Bhatia, M. S., & Gupta, L. K. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.173073 · Cited by 19
Ginsberg, L. D. (2009) · CNS Spectrums · doi:10.1017/s1092852900026353 · Cited by 19
Borumand, M. R., Motaghinejad, M., Motevalian, M., & Gholami, M. (2019) · Europe PMC (PubMed Central) · doi:10.30476/ijms.2019.44515 · Cited by 19
Goel, Y., Fouda, R., & Gupta, K. (2022) · Antioxidants · doi:10.3390/antiox11020265 · Cited by 16
“Duloxetine, a serotonin-norepinephrine reuptake inhibitor, has been used to manage depression and anxiety [106].”
Shared comorbidity of depression, migraine, insomnia, and fibromyalgia in a population-based sample
Lee, W., Shin, H. J., Min, I. K., Kim, C., Kim, K. M., Heo, K., & Chu, M. K. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.03.077 · Cited by 22
David, P., Quail, D., Gandhi, P., Walker, D. J., & Peveler, R. (2007) · Journal of Affective Disorders · doi:10.1016/j.jad.2007.08.023 · Cited by 17
Li, G., Wang, X., & Ma, D. (2016) · Clinical Drug Investigation · doi:10.1007/s40261-016-0396-9 · Cited by 19
Use of effect size to determine optimal dose of duloxetine in major depressive disorder
Pritchett, Y., Marciniak, M. D., Corey‐Lisle, P. K., Berzon, R. A., Desaiah, D., & Detke, M. J. (2006) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.06.013 · Cited by 18
Duloxetine in the treatment of generalized anxiety disorder
Norman, T. R. (2009) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s2820 · Cited by 18
“In two of the studies (Goldstein et al 2002; Goldstein et al 2004), data from the Hamilton Anxiety Rating Scale (HAM-A) were also available.”
van Baardewijk, M., Vis, P., & Einarson, T. R. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x56484 · Cited by 18
Drug Class Review: Second-Generation Antidepressants
Gartlehner, G., Hansen, R. A., Reichenpfader, U., Kaminski, A., Kien, C., Strobelberger, M., Noord, M. V., Thieda, P., Thaler, K. J., & Gaynes, B. N. (2011) · Cited by 17
Metadata
- Authors
- Goldstein, D. J., Mallinckrodt, C., Lu, Y., & Demitrack, M. A.
- Affiliations
- Eli Lilly (United States) (US)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2002-03-15
- Volume
- 63
- Issue
- 3
- Pages
- 225-231
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2003363634
- Cited by
- 334
- References
- 0
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 4 · 2023: 1 · 2022: 3 · 2021: 2 · 2020: 9 · 2019: 9 · 2018: 7 · 2017: 6 · 2016: 13 · 2015: 12 · 2014: 11 · 2013: 14 · 2012: 10
- FWCI
- 17.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
- Keywords
- duloxetine, major depressive disorder, serotonin-norepinephrine reuptake inhibitors, fluoxetine, antidepressant efficacy, drug safety and tolerability, treatment response and remission, insomnia, asthenia, adverse events
- MeSH terms
- Duloxetine Hydrochloride, Adult, Antidepressive Agents, Blood Pressure, Body Weight, Major Depressive Disorder, Double-Blind Method, Drug Administration Schedule, Female, Fluoxetine, Humans, Male, Middle Aged, Thiophenes, Treatment Outcome, Outcome Assessment, Health Care, Selective Serotonin Reuptake Inhibitors, Adrenergic Uptake Inhibitors, Dopamine Uptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
